Nanotechnology Now - Press Release: AMAG Pharmaceuticals, Inc. to Host Conference Call on July 29, 2008 to Discuss Financial Results for the Quarter Ended June 30, 2008

Home > Press > AMAG Pharmaceuticals, Inc. to Host Conference Call on July 29, 2008 to Discuss Financial Results for the Quarter Ended June 30, 2008

Abstract:
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended June 30, 2008 before the U.S. financial markets open on Tuesday, July 29, 2008. The announcement will be followed by a conference call at 8:30 a.m. ET during which management will discuss the Company's financial results, business highlights and its development programs.

AMAG Pharmaceuticals, Inc. to Host Conference Call on July 29, 2008 to Discuss Financial Results for the Quarter Ended June 30, 2008

Cambridge, MA | Posted on July 21st, 2008

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (706) 902-1303 for international access. A telephone replay will be available from approximately 10:00 a.m. ET on July 29, 2008 through midnight July 31, 2008. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The passcode for the live call and replay is 56344417.

An audio webcast of the call will be available through the Investors section of the Company's website at www.amagpharma.com. The webcast replay will be available from approximately 10:00 a.m. ET on July 29, 2008 through midnight August 29, 2008.

####

About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia and as a diagnostic agent for vascular-enhanced magnetic resonance imaging to assess peripheral arterial disease. The Company submitted a New Drug Application for marketing approval of ferumoxytol as an intravenous iron replacement therapy in chronic kidney disease patients with the FDA in December 2007, which was accepted for filing by the FDA in February 2008.

For more information, please click here

Contacts:
AMAG Pharmaceuticals, Inc.
Kristen Galfetti
617-498-3362

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: